Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model.
T cell response
adenovirus
antibody
influenza A virus
influenza B virus
oxygen exchange
pulmonary function
recombinant adenovirus
universal influenza vaccine
vaccine safety
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
12 04 2021
12 04 2021
Historique:
received:
21
12
2020
accepted:
17
02
2021
pubmed:
26
2
2021
medline:
20
4
2021
entrez:
25
2
2021
Statut:
epublish
Résumé
Current influenza vaccines, live attenuated or inactivated, do not protect against antigenically novel influenza A viruses (IAVs) of pandemic potential, which has driven interest in the development of universal influenza vaccines. Universal influenza vaccine candidates targeting highly conserved antigens of IAV nucleoprotein (NP) are promising as vaccines that induce T cell immunity, but concerns have been raised about the safety of inducing robust CD8 T cell responses in the lungs. Using a mouse model, we systematically evaluated effects of recombinant adenovirus vectors (rAd) expressing IAV NP (A/NP-rAd) or influenza B virus (IBV) NP (B/NP-rAd) on pulmonary inflammation and function after vaccination and following live IAV challenge. After A/NP-rAd or B/NP-rAd vaccination, female mice exhibited robust systemic and pulmonary vaccine-specific B cell and T cell responses and experienced no morbidity (e.g., body mass loss). Both
Identifiants
pubmed: 33627390
pii: JVI.02359-20
doi: 10.1128/JVI.02359-20
pmc: PMC8104105
pii:
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400007C
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL140623
Pays : United States
Organisme : NIH HHS
ID : T32 OD011089
Pays : United States
Organisme : NIA NIH HHS
ID : U54 AG062333
Pays : United States
Informations de copyright
Copyright © 2021 American Society for Microbiology.
Références
Sci Transl Med. 2012 Jan 4;4(115):115ra1
pubmed: 22218690
Cell. 2016 Jul 28;166(3):596-608
pubmed: 27453466
Science. 2009 Apr 10;324(5924):246-51
pubmed: 19251591
J Appl Physiol (1985). 2011 May;110(5):1455-9
pubmed: 21310888
PLoS One. 2019 Apr 15;14(4):e0215321
pubmed: 30986224
Nat Med. 2013 Oct;19(10):1305-12
pubmed: 24056771
J Virol. 1994 Jan;68(1):517-20
pubmed: 8254764
NPJ Vaccines. 2019 Jul 12;4:29
pubmed: 31312529
Am J Epidemiol. 2018 Dec 1;187(12):2603-2614
pubmed: 30084906
PLoS One. 2016 Apr 07;11(4):e0153195
pubmed: 27055234
Mol Ther. 2014 Mar;22(3):668-674
pubmed: 24374965
JAMA. 2009 Nov 4;302(17):1888-95
pubmed: 19822628
J Infect Dis. 2018 Jul 2;218(3):347-354
pubmed: 29506129
Immunity. 1998 Jun;8(6):683-91
pubmed: 9655482
Lancet. 2018 Jul 21;392(10143):232-243
pubmed: 30047376
J Exp Med. 1998 Jul 20;188(2):223-32
pubmed: 9670035
Vaccine. 2009 Nov 5;27(47):6512-21
pubmed: 19729082
Am J Respir Crit Care Med. 2015 Jun 15;191(12):1422-31
pubmed: 25844934
J Virol. 1987 Apr;61(4):1098-102
pubmed: 3493353
J Infect Dis. 2018 Jul 13;218(4):633-644
pubmed: 29669026
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
J Exp Med. 1984 Aug 1;160(2):552-63
pubmed: 6206181
Vaccine. 2018 Aug 6;36(32 Pt B):4910-4918
pubmed: 30037481
Vaccine. 2005 Nov 16;23(46-47):5404-10
pubmed: 16011865
J Clin Invest. 2016 Apr 1;126(4):1245-7
pubmed: 26999598
J Gen Virol. 1987 Feb;68 ( Pt 2):433-40
pubmed: 3493324
PLoS One. 2010 Oct 04;5(10):e13162
pubmed: 20976273
Am J Physiol Lung Cell Mol Physiol. 2018 Oct 1;315(4):L517-L525
pubmed: 29847990
Am J Physiol Lung Cell Mol Physiol. 2015 Oct 1;309(7):L662-76
pubmed: 26232300
Front Immunol. 2020 May 19;11:909
pubmed: 32508823
Scand J Immunol. 1988 Jul;28(1):81-5
pubmed: 2456608
Sci Rep. 2016 Feb 01;6:20137
pubmed: 26831578
Ir Med J. 2013 Sep;106(8):249-52
pubmed: 24282900
PLoS Pathog. 2010 Oct 14;6(10):e1001145
pubmed: 20976194
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
Compr Physiol. 2012 Jul;2(3):1921-35
pubmed: 23723029
Mol Ther. 2010 Dec;18(12):2182-9
pubmed: 20877342
Lancet. 2020 Sep 26;396(10255):887-897
pubmed: 32896291
Science. 1993 Mar 19;259(5102):1745-9
pubmed: 8456302
Curr Opin Virol. 2013 Aug;3(4):430-7
pubmed: 23721864
EBioMedicine. 2018 Mar;29:146-154
pubmed: 29519670
Immunology. 1990 Aug;70(4):540-6
pubmed: 2168340
Vaccine. 2003 Jun 2;21(19-20):2616-26
pubmed: 12744898
Influenza Other Respir Viruses. 2018 Sep;12(5):643-648
pubmed: 29676537
BMJ Open. 2015 Oct 28;5(10):e008748
pubmed: 26510727
N Engl J Med. 2016 Apr 28;374(17):1635-46
pubmed: 25629663
Respir Res. 2008 Jun 12;9:51
pubmed: 18549493
J Immunol. 1998 Jan 1;160(1):322-7
pubmed: 9551987
J Immunol. 1981 Mar;126(3):1036-41
pubmed: 6970211
J Immunol. 2004 Aug 1;173(3):1978-86
pubmed: 15265932
Am J Respir Cell Mol Biol. 2011 Jan;44(1):34-9
pubmed: 20118224
J Virol. 2019 Oct 15;93(21):
pubmed: 31391269
PLoS One. 2011;6(7):e21937
pubmed: 21789196
Nat Med. 1999 Oct;5(10):1157-63
pubmed: 10502819
J Vis Exp. 2015 Jan 06;(95):e52216
pubmed: 25590416
Front Immunol. 2016 Feb 05;7:25
pubmed: 26904022
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
Vaccine. 2007 Sep 28;25(39-40):6845-51
pubmed: 17728024
J Biol Chem. 2008 Apr 25;283(17):11382-7
pubmed: 18252707
J Immunol. 2008 Sep 15;181(6):4168-76
pubmed: 18768874
Emerg Infect Dis. 2007 Mar;13(3):426-35
pubmed: 17552096
Vaccine. 1999 Nov 12;18(7-8):623-32
pubmed: 10547421